Elevated IL-17A levels in early stages of bladder cancer regardless of smoking status

Future Oncology

Volumn 9, Issue 2, 2013, Pages 295-304

  Doroudchi, Mehrnoosh ^a   Saidi, Mohadesatosadat ^a   Malekzadeh, Mahyar ^b   Golmoghaddam, Hossein ^a   Khezri, Abdulaziz ^a   Ghaderi, Abbas ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

bladder cancer; IL 17A; serum; smoking; stage

Indexed keywords

INTERLEUKIN 17; NICOTINE; OPIATE;

ADULT; ARTICLE; BLADDER CANCER; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; SMOKING; TRANSITIONAL CELL CARCINOMA;

CASE-CONTROL STUDIES; HUMANS; INTERLEUKIN-17; NEOPLASM GRADING; NEOPLASM STAGING; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 84874055474     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.180     Document Type: Article

References (69)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
3. Mousavi M. Iranian Annual National Cancer Registration Report 2005-2006. Ministry of Health and Medical Education, Tehran, Iran, 337 (2006).
4. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 431, 405-406 (2004).
5. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124, 823-835 (2006).
6. Zhang B, Rong G, Wei H et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374, 533-537 (2008).
7. Sfanos KS, Bruno TC, Maris CH et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer. Res. 14, 3254-3261 (2008).
8. Kryczek I, Wei S, Zou L et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor J. Immunol. 178, 6730-6733 (2007).
9. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin. Immunol. 19, 362-371 (2007).
10. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 21, 467-476 (2004).
11. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28, 454-467 (2008).
12. Turner JE, Paust HJ, Steinmetz OM, Panzer U. The Th17 immune response in renal inflammation. Kidney Int. 77(12), 1070-1075 (2010).
13. Numasaki M, Fukushi J, Ono M et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620-2627 (2003).
14. Benchetrit F, Ciree A, Vives V et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99, 2114-2121 (2002).
15. Martin-Orozco N, Muranski P, Chung Y et al. Th17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5), 787-798 (2009).
16. Steiner GE, Newman ME, Paikl D et al. Expression and function of pro-inflammatory interleukin IL17 and IL17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56, 171-182 (2003).
17. Kato T, Furumoto H, Ogura T et al. Expression of IL17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 282, 735-738 (2001).
18. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4+ IL17-producing T cells in ovarian cancer. Proc. Natl Acad. Sci. USA 105(40), 15505-15510 (2008).
19. Maruyama T, Kono K, Mizukami Y et al. Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci. 101(9), 1947-1954 (2010).
20. Iida T, Iwahashi M, Katsuda M et al. Tumor-infiltrating CD4+ Th17 cells produce IL17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol. Rep. 25(5), 1271-1277 (2011).
21. Volpe E, Servant N, Zollinger R et al. A critical function for transforming growth factor-b, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9, 650-657 (2008).
22. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 184, 1630-1641 (2010).
23. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27, 660-669 (2007).
24. Evans HG, Suddason T, Jackson I, Taams LS, Lord GM. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc. Natl Acad. Sci. USA 104, 17034-17039 (2007).
25. Tanaka J, Watanabe N, Kido M et al. Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin. Exp. Allergy 39, 89-100 (2009).
26. Chi LJ, Lu HT, Li GL et al. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin. Exp. Immunol. 161(3), 480-489 (2010).
27. Yang MH, Yen CC, Chen PM et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur. Urol. (7 Suppl.), 618-626 (2008).
28. Baris D, Karagas MR, Verrill C et al. A case-control study of smoking and bladder cancer risk: emergent patterns over time. J. Natl. Cancer Inst. 101, 1553-1561 (2009).
29. Vineis P, Kogevinas M, Simonato L, Brennan P, Boffetta P. Levelling-off of the risk of lung and bladder cancer in heavy smokers: an analysis based on case-control studies and a metabolic interpretation. Mutat. Res. 463(1), 103-110 (2000).
30. Domagala Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J. Phys. Pharmacol. 59 Suppl 6, 19-34 (2008).
31. Mancini NM, Bene MC, Gerard H et al. Early effects of short-time cigarette smoking on the human lung: A study of bronchoalveolar lavage fluids. Lung 171, 277-291 (1993).
32. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir. Res. 6, 68 (2005).
33. Noakes PS, Hale J, Thomas R, Lane C, Devadson SG, Prescott SL. Maternal smoking is associated with impaired neonatal toll-like receptor-mediated immune responses. Eur. Respir. J. 28, 721-729 (2006).
34. Qian J, Galitovskiy V, Chernyavsky AI, Marchenko S, Grando SA. Plasticity of the murine spleen T-cell cholinergic receptors and their role in in vitro differentiation of naive CD4 T cells toward the Th1, Th2 and Th17 lineages. Genes Immun. 12(3), 222-230 (2011).
35. Kondo Y, Tachikawa E, Ohtake S et al. Inflammatory cytokines decrease the expression of nicotinic acetylcholine receptor during the cell maturation. Mol. Cell Biochem. 333(1-2), 57-64 (2010).
36. Galitovskiy V, Qian J, Chernyavsky AI et al. Cytokine-induced alterations of a7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17-versus Th2-mediated colitis. J. Immunol. 187(5), 2677-2687 (2011).
37. Singh SP, Kalra R, Puttfarcken P, Kozak A, Tesfaigzi J, Sopori ML. Acute and chronic nicotine exposures modulate the immune system through different pathways. Toxicol. Appl. Pharmacol. 164, 65-72 (2000).
38. Sopori ML, Kozak W, Savage SM et al. Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms. Psychoneuroendocrinology 23, 189-204 (1998).
39. Pullan RD, Rhodes J, Ganesh S et al. Transdermal nicotine for active ulcerative colitis. N. Engl. J. Med. 330(12), 811-815 (1994).
40. Sandborn WJ, Tremaine WJ, Offord KP et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 126, 364-371 (1997).
41. McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. (4), CD004722 (2004).
42. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J. Immunol. 183(10), 6681-6688 (2009).
43. Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 109, 365-373 (2003).
44. Nouri-Shirazi M, Tinajero R, Guinet E. Nicotine alters the biological activities of developing mouse bone marrow-derived dendritic cells (DCs). Immunol. Lett. 109, 155-164 (2007).
45. Gohji K, Fujimoto N, Komiyama T et al. Elevation of serum levels of matrix metalloproteinase-2 and-3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78(11), 2379-2387 (1996).
46. Gohji K, Fujimoto N, Fujii A, Komiyama T, Okawa J, Nakajima M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 56(14), 3196-3198, (1996).
47. Gakis G, Todenhöfer T, Renninger M et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 108(11), 1800-1805 (2011).
48. Radosavljevic G, Ljujic B, Jovanovic I et al. Interleukin-17 may be valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 57(2), 135-144 (2010).
49. Zhu X, Mulcahy LA, Mohammed RA et al. IL17 expression by breast-cancer-associated macrophages: IL promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 10(6), R95 (2008).
50. Li J, Mo HY, Xiong G et al. Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J. Biol. Chem. 287(42), 35484-35495 (2012).
51. Giuntoli RL 2nd, Webb TJ, Zoso A et al. Ovarian cancer-associated ascites demonstrates altered immune environment:implications for anti-tumor immunity. Anticancer Res. 29(8), 2875-2884 (2009).
52. Shime H, Yabu M, Akazawa T et al. Tumor-secreted lactic acid promotes IL-23/IL17 proinflammatory pathway. J. Immunol. 180(11), 7175-7183 (2008).
53. Krejsgaard T, Ralfkiaer U, Clasen-Linde E et al. Malignant cutaneous T-cell lymphoma cells express IL17 utilizing the Jak3/Stat3 signaling pathway. J. Invest. Dermatol. 131(6), 1331-1338 (2011).
54. Numasaki M, Watanabe M, Suzuki T et al. IL17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 175(9), 6177-6189 (2005).
55. Hirata T, Osuga Y, Takamura M et al. Recruitment of CCR6-expressing Th17 cells by CCL 20 secreted from IL1 beta-, TNF-alpha-, and IL17A-stimulated endometriotic stromal cells. Endocrinology 151(11), 5468-5476 (2010).
56. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51(1), 154-164 (2010).
57. Gakis G, Todenhöfer T, Stenzl A. The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Curr. Opin. Urol. 21(5), 428-433 (2011).
58. Gakis G, Schwentner C, Todenhöfer T, Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int. 233-237 (2012).
59. Zhang S, Zheng M, Kibe R, Huang Y, Marrero L, Warren S, Zieske AW, Iwakuma T, Kolls JK, Cui Y. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J. 25(7), 2387-2398 (2011).
60. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1, 54(3), 784-788 (1994).
61. Salehi A, Khezri AA, Malekmakan L, Aminsharifi A. Epidemiologic status of bladder cancer in Shiraz, Southern Iran. Asian. Pac. J. Cancer. Prev. 12(5), 1323-1327 (2011).
62. Eissenberg T, Shihadeh A. Waterpipe tobacco and cigarette smoking direct comparison of toxicant exposure. Am. J. Prev. Med. 37(6), 518-523 (2009).
63. Chernyavsky AI, Arredondo J, Skok M, Grando SA. Auto/paracrine control of inflammatory cytokines by acetylcholine in macrophage-like U937 cells through nicotinic receptors. Int. Immunopharmacol. 10(3), 308-315 (2010).
64. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2(52), 52-72 (2010).
65. Vakkila J, Lotze MT, Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 4(8), 641-648 (2004).
66. Zhu Z, Shen Z, Xu C. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm. 2012, 528690 (2012).
67. Mantovani A. Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 10(4), 369-373 (2010).
68. Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366(13), 1190-1199 (2012).
69. Wu CH, Lee CH, Ho YS. Nicotinic acetylcholine receptor-based blockade: of molecular targets for cancer therapy. Clin. Cancer Res. 17(11), 3533-3541 (2011).